William A. Rees

3.6k total citations
59 papers, 2.7k citations indexed

About

William A. Rees is a scholar working on Immunology, Molecular Biology and Pathology and Forensic Medicine. According to data from OpenAlex, William A. Rees has authored 59 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Immunology, 18 papers in Molecular Biology and 14 papers in Pathology and Forensic Medicine. Recurrent topics in William A. Rees's work include Monoclonal and Polyclonal Antibodies Research (14 papers), Multiple Sclerosis Research Studies (11 papers) and T-cell and B-cell Immunology (11 papers). William A. Rees is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (14 papers), Multiple Sclerosis Research Studies (11 papers) and T-cell and B-cell Immunology (11 papers). William A. Rees collaborates with scholars based in United States, Germany and France. William A. Rees's co-authors include Philippa Marrack, John W. Kappler, Ross M. Kedl, Peter H. von Hippel, David A. Hildeman, Brian C. Schaefer, Tom Mitchell, Thomas D. Yager, Jeremy Bender and T. Kent Teague and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and Nature Medicine.

In The Last Decade

William A. Rees

58 papers receiving 2.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
William A. Rees United States 23 1.2k 852 486 243 237 59 2.7k
Pierre‐Yves Mantel Switzerland 28 1.7k 1.5× 1.4k 1.6× 222 0.5× 539 2.2× 265 1.1× 43 3.6k
David C. Benjamin United States 35 1.5k 1.2× 1.7k 1.9× 390 0.8× 277 1.1× 601 2.5× 106 4.3k
Jorge L. Martínez‐Torrecuadrada Spain 32 675 0.6× 1.2k 1.4× 191 0.4× 110 0.5× 467 2.0× 62 2.7k
Alexander Miller United States 22 1.7k 1.5× 1.1k 1.3× 320 0.7× 111 0.5× 178 0.8× 53 3.1k
Matthias Wabl United States 41 3.0k 2.5× 2.7k 3.1× 505 1.0× 238 1.0× 420 1.8× 127 5.6k
William R. Green United States 29 1.1k 0.9× 683 0.8× 254 0.5× 201 0.8× 400 1.7× 110 3.0k
Michael Brigham‐Burke United States 22 886 0.8× 1.3k 1.5× 145 0.3× 202 0.8× 170 0.7× 30 2.6k
Thomas Hoffman United States 25 1.5k 1.3× 1.0k 1.2× 271 0.6× 201 0.8× 279 1.2× 74 2.9k
Elisabetta Padovan Switzerland 26 3.0k 2.5× 664 0.8× 227 0.5× 205 0.8× 836 3.5× 48 4.0k
Roland Newman United States 32 1.5k 1.3× 2.1k 2.5× 242 0.5× 228 0.9× 577 2.4× 69 4.3k

Countries citing papers authored by William A. Rees

Since Specialization
Citations

This map shows the geographic impact of William A. Rees's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William A. Rees with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William A. Rees more than expected).

Fields of papers citing papers by William A. Rees

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by William A. Rees. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William A. Rees. The network helps show where William A. Rees may publish in the future.

Co-authorship network of co-authors of William A. Rees

This figure shows the co-authorship network connecting the top 25 collaborators of William A. Rees. A scholar is included among the top collaborators of William A. Rees based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with William A. Rees. William A. Rees is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bennett, Jeffrey L., Sean J. Pittock, Friedemann Paul, et al.. (2024). B cell and aquaporin‐4 antibody relationships with neuromyelitis optica spectrum disorder activity. Annals of Clinical and Translational Neurology. 11(10). 2792–2798. 4 indexed citations
2.
Clair, E. William St., Alan N. Baer, Wan‐Fai Ng, et al.. (2024). CD40 ligand antagonist dazodalibep in Sjögren’s disease: a randomized, double-blinded, placebo-controlled, phase 2 trial. Nature Medicine. 30(6). 1583–1592. 21 indexed citations
3.
Cree, Bruce, Ho Jin Kim, Brian G. Weinshenker, et al.. (2024). Safety and efficacy of inebilizumab for the treatment of neuromyelitis optica spectrum disorder: end-of-study results from the open-label period of the N-MOmentum trial. The Lancet Neurology. 23(6). 588–602. 20 indexed citations
4.
Li, Wang, Ilias Alevizos, William A. Rees, et al.. (2023). OP0143 EFFICACY AND SAFETY OF DAZODALIBEP (VIB4920/HZN4920) IN SUBJECTS WITH SJÖGREN'S SYNDROME: A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PROOF OF CONCEPT STUDY. Annals of the Rheumatic Diseases. 82. 95–95. 3 indexed citations
5.
Aktaş, Orhan, Hans‐Peter Hartung, William A. Rees, et al.. (2023). Serum neurofilament light chain levels at attack predict post-attack disability worsening and are mitigated by inebilizumab: analysis of four potential biomarkers in neuromyelitis optica spectrum disorder. Journal of Neurology Neurosurgery & Psychiatry. 94(9). 757–768. 20 indexed citations
6.
Kim, Ho Jin, Orhan Aktaş, Kristina R. Patterson, et al.. (2023). Inebilizumab reduces neuromyelitis optica spectrum disorder risk independent of FCGR3A polymorphism. Annals of Clinical and Translational Neurology. 10(12). 2413–2420. 8 indexed citations
7.
Clair, E. William St., Ilias Alevizos, William A. Rees, et al.. (2023). LB0003 Dazodalibep (VIB4920/HZN4920) in Sjögren's Subjects with an Unacceptable Symptom Burden: Safety and Efficacy from a Phase 2, Randomized, Double-Blind Study. Annals of the Rheumatic Diseases. 82. 201–201. 1 indexed citations
8.
9.
Kim, Ho Jin, et al.. (2021). Inebilizumab Treatment Reduces The Occurrence Of Pain In NMOSD Patients (2319). Neurology. 96(15_supplement). 1 indexed citations
10.
Marignier, Romain, Sean J Pittock, Friedemann Paul, et al.. (2021). AQP4-IgG-seronegative patient outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder. Multiple Sclerosis and Related Disorders. 57. 103356–103356. 24 indexed citations
11.
Cree, Bruce, Jeffrey L. Bennett, Brian G. Weinshenker, et al.. (2021). Long Term Safety Outcomes with Inebilizumab Treatment in NMOSD: the N-MOmentum Trial (2283). Neurology. 96(15_supplement). 2 indexed citations
12.
Smith, Michael A., Chia-Chien Chiang, Kamelia Zerrouki, et al.. (2020). Using the circulating proteome to assess type I interferon activity in systemic lupus erythematosus. Scientific Reports. 10(1). 4462–4462. 18 indexed citations
13.
Sands, Bruce E., Jingjing Chen, Brian G. Feagan, et al.. (2017). Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, in Patients With Moderate to Severe Crohn’s Disease: A Phase 2a Study. Gastroenterology. 153(1). 77–86.e6. 223 indexed citations
14.
Gilst, Marc R. Van, et al.. (2005). A Quantitative Description of the Binding States and In Vitro Function of Antitermination Protein N of Bacteriophage λ. Journal of Molecular Biology. 348(5). 1039–1057. 5 indexed citations
15.
Marrack, Philippa, Jeremy Bender, Michael Jordan, et al.. (2001). Presidential Address to The American Association of Immunologists. The Journal of Immunology. 167(2). 617–621. 19 indexed citations
16.
Hawkins, J. D., William A. Rees, George D. Mundy, Scott D. Stanley, & Thomas Tobin. (1998). An overview of the methylxanthines and their regulation in the horse. Equine practice. 20(1). 10–16. 11 indexed citations
17.
Rees, William A., et al.. (1997). Regulation of the elongation-termination decision at intrinsic terminators by antitermination protein N of phage λ 1 1Edited by K. Yamamoto. Journal of Molecular Biology. 273(4). 797–813. 48 indexed citations
18.
Ignatowicz, Leszek, William A. Rees, Rafał Pacholczyk, et al.. (1997). T Cells Can Be Activated by Peptides That Are Unrelated in Sequence to Their Selecting Peptide. Immunity. 7(2). 179–186. 100 indexed citations
19.
Harkins, J.D., George D. Mundy, S. Stanley, et al.. (1996). Determination of highest no effect dose (HNED) for local anaesthetic responses to procaine, cocaine, bupivacaine and benzocaine. Equine Veterinary Journal. 28(1). 30–37. 23 indexed citations
20.
Rees, William A., Rebecca W. Keller, James Vesenka, Guoliang Yang, & Carlos Bustamante. (1993). Evidence of DNA Bending in Transcription Complexes Imaged by Scanning Force Microscopy. Science. 260(5114). 1646–1649. 157 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Pierre‐Yves Mantel Breakdown of academic impact, for papers by David C. Benjamin Breakdown of academic impact, for papers by Jorge L. Martínez‐Torrecuadrada Breakdown of academic impact, for papers by Alexander Miller Breakdown of academic impact, for papers by Matthias Wabl Breakdown of academic impact, for papers by William R. Green Breakdown of academic impact, for papers by Michael Brigham‐Burke Breakdown of academic impact, for papers by Thomas Hoffman Breakdown of academic impact, for papers by Elisabetta Padovan Breakdown of academic impact, for papers by Roland Newman
Rankless by CCL
2026